Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01009463 · ClinicalTrials.gov registry record · Phase 3
A Study to Evaluate the Efficacy and Safety of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
A Phase 3 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,626
- Enrollment target
NCT01009463 is a Phase 3 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 1,626 participants.
The verdict
NCT01009463, a Phase 3 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,626 participants
- Enrollment target
Study Summary
The Purpose of this study is to assess the efficacy and safety of three strengths of the FF/GW642444 Inhalation Powder in subject with Chronic Obstructive Pulmonary Disease (COPD)
Interventions
- DRUG FF/GW642444 Inhalation Powder
- DRUG GW642444 Inhalation Powder
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,626 participants |
| Start Date | 2009-09-25 |
| Est. Completion | 2011-10-31 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01009463
The ClinicalTrials.gov registry entry for NCT01009463 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 1,626 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which FF/GW642444 Inhalation Powder is the first listed.
NCT01009463 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01009463 about?
NCT01009463 is a clinical study titled "A Study to Evaluate the Efficacy and Safety of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD)". The Purpose of this study is to assess the efficacy and safety of three strengths of the FF/GW642444 Inhalation Powder in subject with Chronic Obstructive Pulmonary Disease (COPD)
What is the current status of trial NCT01009463?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,626 participants. The study started on 2009-09-25. Estimated completion is 2011-10-31.
What interventions are being tested in trial NCT01009463?
The interventions under investigation include: FF/GW642444 Inhalation Powder (DRUG), GW642444 Inhalation Powder (DRUG).
Who is sponsoring clinical trial NCT01009463?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.